PAR Share Price Performance
AU$0.33
0.05 (20.37%)
94.1% undervalued intrinsic discount
AU$5.50
Fair Value
Price AU$0.33
AmirV AU$5.50
Fair ValueAU$5.50
Share Pricen/a
Weekly Picks: 💻 A Hedge Against US Government Shutdown And 2 More Picks
Oct 21
Paradigm Biopharmaceuticals Limited Stock Price
- 1 Narratives written by author
- 3 Comments on narratives written by author
- 92 Fair Values set on narratives written by author
PAR Community Narratives
AM
Fair Value AU$5.5 94.1% undervalued intrinsic discount
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
19users have liked this narrative
3users have commented on this narrative
68users have followed this narrative
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.Read more
19users have liked this narrative
3users have commented on this narrative
68users have followed this narrative
AM
AU$5.5
94.1% undervalued intrinsic discount
AmirV Fair Value
Revenue growth
N/A
Profit Margin
21.34%
Future PE
29.36x
Share price in 2030
AU$0
Recently Updated Narratives
AM
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Fair Value: AU$5.5 94.1% undervalued intrinsic discount
68 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Paradigm Biopharmaceuticals Limited Key Details
About PAR
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Recent PAR News & Updates
